SUSCA, SARA
SUSCA, SARA
SCIENZE MEDICHE
"Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors
2022-01-01 Mastorino, Luca; Susca, Sara; Cariti, Caterina; Verrone, Anna; Stroppiana, Elena; Ortoncelli, Michela; Dapavo, Paolo; Ribero, Simone; Quaglino, Pietro
A new suture technique for flap closure in dermatologic surgery
2022-01-01 Parietti, Michele; Susca, Sara; Ribero, Simone
Anti-IL23 in inflammatory bowel disease patients with dermatological indication: The shared gastroenterological-dermatological clinic experience
2024-01-01 Ribaldone D.G.; Palumbo A.; Susca S.; Merli M.; Dapavo P.; Vernero M.
Brodalumab efficacy in bio-naïve psoriasis patients: real-life experience of 202 subjects up to 48 weeks
2022-01-01 Mastorino, Luca; Cariti, C; Susca, S; Boskovic, S; Aquino, C; Ortoncelli, M; Stroppiana, E; Verrone, A; Dapavo, P; Quaglino, P; Ribero, Simone
Clinical characteristics and response to biological therapies for inverse psoriasis: a real‐life comparison between the therapeutic effects of anti‐IL‐23 and anti‐IL‐17 agents
2024-01-01 Mastorino, Luca; Dapavo, Paolo; Macagno, Nicole; Ortoncelli, Michela; Verrone, Anna; Stroppiana, Elena; Cariti, Caterina; Susca, Sara; Siliquini, Niccolò; di Corteranzo, Isotta Giunipero; Quaglino, Pietro; Ribero, Simone
Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real-life experience on 638 patients with psoriasis
2023-01-01 Mastorino, Luca; Cariti, Caterina; Susca, Sara; Siliquini, Niccolò; Verrone, Anna; Stroppiana, Elena; Ortoncelli, Michela; Dapavo, Paolo; Quaglino, Pietro; Ribero, Simone
Comparison of Secukinumab and Ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients
2022-01-01 Cariti, C; Dapavo, P; Mastorino, L; Ortoncelli, M; Siliquini, N; Merli, M; Avallone, G; Giordano, S; Fabrizio, R; Susca, S; Verrone, A; Stroppiana, E; Quaglino, P; Ribero, S
Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment
2023-01-01 Mastorino, Luca; Dapavo, Paolo; Susca, Sara; Cariti, Caterina; Siliquini, Niccolò; Verrone, Anna; Stroppiana, Elena; Ortoncelli, Michela; Quaglino, Pietro; Ribero, Simone
Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents
2023-01-01 Roccuzzo, Gabriele; Mastorino, Luca; Susca, Sara; Cariti, Caterina; Passerini, Stefania G; Sciamarrelli, Nadia; Borriello, Silvia; Macagno, Nicole; Sliquini, Niccolò; Avallone, Gianluca; Verrone, Anna; Stroppiana, Elena; Quaglino, Pietro; Ortoncelli, Michela; Dapavo, Paolo; Ribero, Simone
Drug survival und klinische Wirksamkeit von Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab und Tildrakizumab in der Behandlung der Psoriasis: Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment
2024-01-01 Mastorino, Luca; Dapavo, Paolo; Susca, Sara; Cariti, Caterina; Siliquini, Niccolò; Verrone, Anna; Stroppiana, Elena; Ortoncelli, Michela; Quaglino, Pietro; Ribero, Simone
Drug Survival, Safety, and Effectiveness of Secukinumab for up to 5 Years in Patients with Psoriasis and Psoriatic Arthritis: A Long-Term Real-Life Experience
2024-01-01 Mastorino, Luca; Dapavo, Paolo; Cariti, Caterina; Susca, Sara; Siliquini, Niccolò; Ortoncelli, Michela; Stroppiana, Elena; Verrone, Anna; Giunipero di Corteranzo, Isotta; Leo, Francesco; Quaglino, Pietro; Ribero, Simone
Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn’s disease
2020-01-01 Vernero M.; Ribaldone D.G.; Cariti C.; Ribero S.; Susca S.; Astegiano M.; Dapavo P.
Effectiveness of Brodalumab on Scalp, Palmoplantar, and Genital Psoriasis: A Descriptive Pilot Study
2023-01-01 Mastorino L.; Celoria V.; Macagno N.; Cariti C.; Susca S.; Siliquini N.; Ortoncelli M.; Stroppiana E.; Verrone A.; Burzi L.; Quaglino P.; Ribero S.; Dapavo P.
Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients
2023-01-01 Mastorino, L; Susca, S; Cariti, C; Sliquini, N; Verrone, A; Stroppiana, E; Ortoncelli, M; Dapavo, P; Ribero, S; Quaglino, P
Mask-related acne flares during the COVID era
2022-01-01 Cariti, Caterina; Cavallo, Francesco; Panzone, Michele; Susca, Sara; Quaglino, Pietro; Ribero, Simone
Oral doxycycline in HIV-related synchronous malignant syphilis and condyloma lata
2022-01-01 Avallone, Gianluca; Cavallo, Francesco; Susca, Sara; Mastorino, Luca; Trunfio, Mattia; Bonora, Stefano; Rugge, Walter; Calleri, Guido; Conti, Luca; Senetta, Rebecca; Marra, Elena; Fierro, Maria T; Quaglino, Pietro; Ribero, Simone
Risankizumab shows faster response in bio naïve than in bio-experienced psoriatic patients
2022-01-01 Mastorino, L; Castelli, F; Stroppiana, E; Verrone, A; Ortoncelli, M; Susca, S; Boskovic, S; Passerini, S G; Macagno, N; Cariti, C; Licciardello, M; Solaroli, C; Pertusi, G; Aragone, M G; Baggini, G; Addese, C; Leporati, C; Peila, R; Giura, M T; Rossotto, G; Pella, P; Mocci, L; Merlo, G; Tiberio, R; Graziola, F; Quaglino, P; Dapavo, P; Ribero, S
Risankizumab shows high efficacy and maintenance in improvement of response until week 52
2022-01-01 Mastorino L.; Susca S.; Megna M.; Siliquini N.; Quaglino P.; Ortoncelli M.; Avallone G.; Rubatto M.; Fabbrocini G.; Dapavo P.; Ribero S.
Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement
2022-01-01 Mastorino, Luca; Cariti, Caterina; Susca, Sara; Sciamarrelli, Nadia; Borriello, Silvia; Ortoncelli, Michela; Stroppiana, Elena; Verrone, Anna; Dapavo, Paolo; Quaglino, Pietro; Ribero, Simone
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| "Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors | 2022 | Mastorino, Luca; Susca, Sara; Cariti, Caterina; Verrone, Anna; Stroppiana, Elena; Ortoncelli, Michela; Dapavo, Paolo; Ribero, Simone; Quaglino, Pietro | |
| A new suture technique for flap closure in dermatologic surgery | 2022 | Parietti, Michele; Susca, Sara; Ribero, Simone | |
| Anti-IL23 in inflammatory bowel disease patients with dermatological indication: The shared gastroenterological-dermatological clinic experience | 2024 | Ribaldone D.G.; Palumbo A.; Susca S.; Merli M.; Dapavo P.; Vernero M. | |
| Brodalumab efficacy in bio-naïve psoriasis patients: real-life experience of 202 subjects up to 48 weeks | 2022 | Mastorino, Luca; Cariti, C; Susca, S; Boskovic, S; Aquino, C; Ortoncelli, M; Stroppiana, E; Verrone, A; Dapavo, P; Quaglino, P; Ribero, Simone | |
| Clinical characteristics and response to biological therapies for inverse psoriasis: a real‐life comparison between the therapeutic effects of anti‐IL‐23 and anti‐IL‐17 agents | 2024 | Mastorino, Luca; Dapavo, Paolo; Macagno, Nicole; Ortoncelli, Michela; Verrone, Anna; Stroppiana, Elena; Cariti, Caterina; Susca, Sara; Siliquini, Niccolò; di Corteranzo, Isotta Giunipero; Quaglino, Pietro; Ribero, Simone | |
| Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real-life experience on 638 patients with psoriasis | 2023 | Mastorino, Luca; Cariti, Caterina; Susca, Sara; Siliquini, Niccolò; Verrone, Anna; Stroppiana, Elena; Ortoncelli, Michela; Dapavo, Paolo; Quaglino, Pietro; Ribero, Simone | |
| Comparison of Secukinumab and Ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients | 2022 | Cariti, C; Dapavo, P; Mastorino, L; Ortoncelli, M; Siliquini, N; Merli, M; Avallone, G; Giordano, S; Fabrizio, R; Susca, S; Verrone, A; Stroppiana, E; Quaglino, P; Ribero, S | |
| Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment | 2023 | Mastorino, Luca; Dapavo, Paolo; Susca, Sara; Cariti, Caterina; Siliquini, Niccolò; Verrone, Anna; Stroppiana, Elena; Ortoncelli, Michela; Quaglino, Pietro; Ribero, Simone | |
| Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents | 2023 | Roccuzzo, Gabriele; Mastorino, Luca; Susca, Sara; Cariti, Caterina; Passerini, Stefania G; Sciamarrelli, Nadia; Borriello, Silvia; Macagno, Nicole; Sliquini, Niccolò; Avallone, Gianluca; Verrone, Anna; Stroppiana, Elena; Quaglino, Pietro; Ortoncelli, Michela; Dapavo, Paolo; Ribero, Simone | |
| Drug survival und klinische Wirksamkeit von Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab und Tildrakizumab in der Behandlung der Psoriasis: Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment | 2024 | Mastorino, Luca; Dapavo, Paolo; Susca, Sara; Cariti, Caterina; Siliquini, Niccolò; Verrone, Anna; Stroppiana, Elena; Ortoncelli, Michela; Quaglino, Pietro; Ribero, Simone | |
| Drug Survival, Safety, and Effectiveness of Secukinumab for up to 5 Years in Patients with Psoriasis and Psoriatic Arthritis: A Long-Term Real-Life Experience | 2024 | Mastorino, Luca; Dapavo, Paolo; Cariti, Caterina; Susca, Sara; Siliquini, Niccolò; Ortoncelli, Michela; Stroppiana, Elena; Verrone, Anna; Giunipero di Corteranzo, Isotta; Leo, Francesco; Quaglino, Pietro; Ribero, Simone | |
| Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn’s disease | 2020 | Vernero M.; Ribaldone D.G.; Cariti C.; Ribero S.; Susca S.; Astegiano M.; Dapavo P. | |
| Effectiveness of Brodalumab on Scalp, Palmoplantar, and Genital Psoriasis: A Descriptive Pilot Study | 2023 | Mastorino L.; Celoria V.; Macagno N.; Cariti C.; Susca S.; Siliquini N.; Ortoncelli M.; Stroppiana E.; Verrone A.; Burzi L.; Quaglino P.; Ribero S.; Dapavo P. | |
| Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients | 2023 | Mastorino, L; Susca, S; Cariti, C; Sliquini, N; Verrone, A; Stroppiana, E; Ortoncelli, M; Dapavo, P; Ribero, S; Quaglino, P | |
| Mask-related acne flares during the COVID era | 2022 | Cariti, Caterina; Cavallo, Francesco; Panzone, Michele; Susca, Sara; Quaglino, Pietro; Ribero, Simone | |
| Oral doxycycline in HIV-related synchronous malignant syphilis and condyloma lata | 2022 | Avallone, Gianluca; Cavallo, Francesco; Susca, Sara; Mastorino, Luca; Trunfio, Mattia; Bonora, Stefano; Rugge, Walter; Calleri, Guido; Conti, Luca; Senetta, Rebecca; Marra, Elena; Fierro, Maria T; Quaglino, Pietro; Ribero, Simone | |
| Risankizumab shows faster response in bio naïve than in bio-experienced psoriatic patients | 2022 | Mastorino, L; Castelli, F; Stroppiana, E; Verrone, A; Ortoncelli, M; Susca, S; Boskovic, S; Passerini, S G; Macagno, N; Cariti, C; Licciardello, M; Solaroli, C; Pertusi, G; Aragone, M G; Baggini, G; Addese, C; Leporati, C; Peila, R; Giura, M T; Rossotto, G; Pella, P; Mocci, L; Merlo, G; Tiberio, R; Graziola, F; Quaglino, P; Dapavo, P; Ribero, S | |
| Risankizumab shows high efficacy and maintenance in improvement of response until week 52 | 2022 | Mastorino L.; Susca S.; Megna M.; Siliquini N.; Quaglino P.; Ortoncelli M.; Avallone G.; Rubatto M.; Fabbrocini G.; Dapavo P.; Ribero S. | |
| Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement | 2022 | Mastorino, Luca; Cariti, Caterina; Susca, Sara; Sciamarrelli, Nadia; Borriello, Silvia; Ortoncelli, Michela; Stroppiana, Elena; Verrone, Anna; Dapavo, Paolo; Quaglino, Pietro; Ribero, Simone |